Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Letter - XYNTHA

Our STN: BL 125264/0

Wyeth Pharmaceuticals, Inc.
Attention: Joyce Schwenk
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Ms. Schwenk:

This letter is in regard to your proposed proprietary names for Antihemophilic Factor (Recombinant), Plasma/Albumin-Free "Xyntha" received on September 26, 2007.

We have considered your proposed proprietary name, "Xyntha" in consultation with CBER's Advertising and Promotional Labeling Branch (APLB) and conclude that under 21 CFR Part 201, the proposed proprietary name "Xyntha" be found acceptable.

If you have any questions, please contact Pauline Cottrell, at (301) 827-6162.

Sincerely yours,

/Basil Golding, M.D./
Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Page Last Updated: 02/13/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English